Merus Labs International Inc (MSL):企業のM&A・提携動向(医療分野)

GlobalDataが発行した調査報告書(GDPH279902D)
◆英語タイトル:Merus Labs International Inc (MSL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:GDPH279902D
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年2月17日
◆ページ数:35
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD500 ⇒換算¥55,000見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD750 ⇒換算¥82,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Merus Labs International Inc (Merus Labs International) formerly Merus Labs Inc, is a specialty pharmaceutical company which offers diversified line of products. Its portfolio encompasses products in various therapeutic areas such as oncology, women’s health, thromboembolic diseases, overactive bladder syndrome, cardiovascular, urology, and infectious disease. The company targets the underdeveloped assets and optimizes their returns and also acquires established products for leveraging its expertise and commercial platform in Canada, Europe, and other markets. The company’s geographic focus spans North America and Europe. It operates through subsidiaries in Luxembourg, British Columbia, the Netherlands, and the US. Merus Labs International is headquartered in Toronto, Ontario, Canada.

Merus Labs International Inc (MSL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Merus Labs International Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Merus Labs International Inc, Medical Devices Deals, 2011 to YTD 2017 10
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 12
Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 13
Merus Labs Acquires Rights to Salagen and Estraderm MX from Novartis Pharma for USD30 Million 14
Merus Labs Acquires Sintrom from Novartis 15
Merus Labs Completes Acquisition Of Prescription Medicine Product From Novartis 16
Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 17
Merus Labs Acquires Canadian Rights Of Vancocin From Iroko International 18
Equity Offering 19
Merus Labs Raises USD21 Million in Private Placement of Shares upon Exercise of Warrants 19
Merus Labs Raises USD20 Million in Private Placement of Subscription Receipts 20
Merus Labs Completes Partial Exercise of Underwriter’s Over Allotment Option for Public Offering of Shares for USD63 Million 22
Merus Labs Raises USD9.2 Million in Private Placement of Preferred Shares 23
Merus Labs Raises USD28.7 Million in Public Offering of Shares 24
Merus Labs International Completes Underwriters Exercise Of Full Over-Allotment Option Of Private Placement Of Shares For US$20.7 Million 25
Merus Labs Completes Private Placement Of Shares For US$4.4 Million 26
Merus Labs Announces Public Offering Of Common Shares For US$10.1 Million 27
Merus Labs Completes Private Placement Of US$0.53 Million 27
Merus Labs International Completes Private Placement For US$2.13 Million 28
Asset Transactions 29
Okana Ventures Acquires North American Product Rights For Factive From Merus Labs For Up to US$3.4 Million 29
Merus Labs International Inc – Key Competitors 32
Key Employees 33
Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Merus Labs International Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Merus Labs International Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Merus Labs International Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Merus Labs International Inc, Medical Devices Deals, 2011 to YTD 2017 10
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 12
Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 13
Merus Labs Acquires Rights to Salagen and Estraderm MX from Novartis Pharma for USD30 Million 14
Merus Labs Acquires Sintrom from Novartis 15
Merus Labs Completes Acquisition Of Prescription Medicine Product From Novartis 16
Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 17
Merus Labs Acquires Canadian Rights Of Vancocin From Iroko International 18
Merus Labs Raises USD21 Million in Private Placement of Shares upon Exercise of Warrants 19
Merus Labs Raises USD20 Million in Private Placement of Subscription Receipts 20
Merus Labs Completes Partial Exercise of Underwriter's Over Allotment Option for Public Offering of Shares for USD63 Million 22
Merus Labs Raises USD9.2 Million in Private Placement of Preferred Shares 23
Merus Labs Raises USD28.7 Million in Public Offering of Shares 24
Merus Labs International Completes Underwriters Exercise Of Full Over-Allotment Option Of Private Placement Of Shares For US$20.7 Million 25
Merus Labs Completes Private Placement Of Shares For US$4.4 Million 26
Merus Labs Announces Public Offering Of Common Shares For US$10.1 Million 27
Merus Labs Completes Private Placement Of US$0.53 Million 27
Merus Labs International Completes Private Placement For US$2.13 Million 28
Okana Ventures Acquires North American Product Rights For Factive From Merus Labs For Up to US$3.4 Million 29
Merus Labs International Inc, Key Competitors 32
Merus Labs International Inc, Key Employees 33
Merus Labs International Inc, Subsidiaries 34

List of Figures
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Merus Labs International Inc, Medical Devices Deals, 2011 to YTD 2017 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Merus Labs International Inc (MSL):企業のM&A・提携動向(医療分野)(Merus Labs International Inc (MSL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆